22 results about "Tumor resistance" patented technology

The invention provides an alkaloid compound as well as a preparation method and an application thereof in tumor resistance. The alkaloid compound provided by the invention shows a remarkable cytotoxic effect on human non-small cell lung cancer cells A549, mouse lung adenocarcinoma cells Lewis, human triple negative breast cancer cells MDA-MB-231 and mouse breast cancer cells 4T1, and can be used for preparing medicines for treating breast cancer, lung cancer and the like.

This invention relates to the application of exosomes in reversing tumor resistance to immune checkpoint (PD-1) inhibitors. A novel application of exosomes in the preparation of pharmaceutical compositions reversing tumor resistance to immune checkpoint inhibitors is disclosed. Exosomes generated from tumor cells recombinantly expressing adenylate cyclase 7 (ADCY7) can significantly reverse tumor resistance to PD-1 inhibitors, and the exosomes exhibit a synergistic effect with the PD-1 inhibitors.

The invention relates to the technical field of medical chemistry and tumor treatment, in particular to application of a novel NOX4 inhibitor ZZU026 and derivatives thereof in tumor resistance and immune response change. The preparation method of the ZZU026 comprises the following steps: replacing N, N-dimethylamino on a benzene ring of GKT137831 with morpholinyl; methoxyl is introduced into the core skeleton. The ZZU026 has a remarkable inhibiting effect on NOX4, has the functions of inhibiting tumor growth, new vascularization and immune-related diseases, regulating and controlling polarization of macrophages and the like, and can inhibit phenotype transformation of macrophages from M1 to M2 and finally inhibit proliferation and immune escape of lung cancer cells; the ZZU026 and the derivatives thereof can be prepared into drugs, health care products, tablets, particles, capsules, oral liquid or injection, and can be used for treating lung cancer and other tumors.

The invention discloses an application of an ARRB1 inhibitor in preparation of a tumor drug resistance reversal agent or a tumor drug sensitizer. It is found that by reducing ARRB1 expression, the sensitivity of human breast cancer cells to etoposide can be improved, the drug resistance of breast cancer etoposide can be reversed, and an ARRB1 inhibitor can be combined with an anti-tumor drug etoposide for use to improve the treatment effect. The invention provides a new direction for research and development of drugs for overcoming breast cancer treatment drug resistance, and has important clinical application value and development value.

The invention relates to the field of biological medicines, in particular to application of an MAGEB16 regulator in preparation of products for treating autoimmune diseases or resisting tumors. The invention provides an application of an MAGEB16 regulator in preparation of a product for treating autoimmune diseases or resisting tumors. The invention also provides an antibody combined with the surface of a tumor cell or an antigen binding fragment thereof. The application finds that the MAGEB16 protein can be expressed on the surface of a tumor cell, so that the technical scheme of directly targeting the MAGEB16 on the surface of the tumor cell through an antibody or a nucleic acid molecule and a series of technical schemes of targeting the MAGEB16 on the surface of the tumor cell become feasible technical schemes, and a new technical scheme is provided for efficient tumor resistance.

The invention belongs to the technical field of biological medicines, and particularly relates to a tumor microenvironment response type nano-drug based on linear-dendritic polymers. The preparation method comprises the following steps: connecting a dendritic fragment to a polymer skeleton through an enzyme-cleavable peptide chain, and coupling a chemotherapeutic drug to a dendritic periphery through a pH-unstable hydrazone bond to obtain an amphiphilic polymer prodrug; the stable nanoparticles are obtained by screening polymeric monomers, can be efficiently taken by tumor cells, and have advantages in tumor tissue penetration and tumor resistance; the polymer prodrug can also load an adenosine receptor antagonist drug to prepare a nano-drug, and the nano-drug reverses adenosine-mediated immunosuppression to realize a synergistic effect of the adenosine receptor antagonist drug and a chemotherapeutic drug; the nano-drug and the PD-1 antibody cooperate to further improve the immune response in vivo and the anti-TNBC effect. The polymer prodrug and nano-drug synthesized by the invention have good prospects in the aspect of treating TNBC.

The invention relates to the technical field of liqueur, in particular to liqueur and a preparation method thereof.The liqueur is prepared by soaking various medicinal and edible raw materials such as kudzuvine roots, rice, barbary wolfberry fruits, smoked plums, grapes, mulberries, poria cocos, Chinese yams, rhizoma polygonati, jujubes and ginseng in baijiu base liquor according to a specific proportion. According to the present invention, the modern analysis technology shows that the wine contains 25 active components such as resveratrol, protocatechuic acid, oleanolic acid, quercetin, kaempferol and the like, and the components achieve the synergistic effect, such that the product has effects of tumor resistance, liver protection, blood sugar reduction, blood fat reduction, oxidation resistance, inflammation resistance, nerve protection and other health-care functions, and the product has characteristics of definite component, synergistic effect, high safety, and no toxic-side effect. The preparation process is stable and controllable, and is suitable for large-scale production.

The present disclosure is directed to the interplay between tumor associated macrophages (TAMs) and tumor cells in the TME. SLC13A3 is demonstrated as a transporter for itaconate in tumor cells and plays a previously unreported role in tumor resistance to ferroptosis and ICB. Compositions and methods for blocking the function of SLC13A3's tumor protecting function are described.

Disclosed are a lactylated NBS1 protein and uses thereof. A lactylation site in this application is lysine at position 388 of NBS1 protein. Lactylation at K388 site of the NBS1 protein activates the DNA repair pathway and has multiple functions, including promoting radiotherapy and chemotherapy resistance in tumor cells and enhancing homologous recombination in DNA repair. By targeted inhibition of the lactylated NBS1 protein, tumor resistance to radiotherapy or chemotherapy can be reversed, providing a potential target for reversing tumor resistance to radiotherapy or chemotherapy.

The present invention relates to the field of medicines, in particular to an anti-tumor effective component of Hedyotis diffusa, a preparation method therefor and the use thereof. Provided in the present invention is the use of one or a combination of kaempferol-3-O-[2-O-(6-O-E-feruloyl)-β-D-glucopyranose]-β-D-pyranose and E-6-O-p-coumaroylpaederoside methyl ester in tumor resistance or the preparation of an anti-tumor drug. The research of the present invention has shown that both a kaempferol-3-O-[2-O-(6-O-E-feruloyl)-β-D-glucopyranose]-β-D-pyranose compound monomer and an E-6-O-p-coumaroylpaederoside methyl ester compound monomer have very strong anti-tumor activity. In the in-vivo anti-tumor activity research, the inhibition rates thereof can reach 48.97% and 45.96%, respectively; and when both are combined to inhibit tumor cells, the research reveals that the two monomers have an obvious effect of synergistically inhibiting tumors.

The invention relates to an anti-prothrombin / phosphatidylserine antibody, a pharmaceutical composition and an application of the anti-prothrombin / phosphatidylserine antibody. The anti-prothrombin / phosphatidylserine antibody provided by the invention is connected with a prothrombin / phosphatidylserine compound with high affinity, so that the antibody is combined with phosphatidylserine in a targeted manner to achieve the treatment of tumor resistance, infection resistance, thrombosis resistance, atherosclerosis, ischemia-reperfusion injury, inflammatory bowel disease, Alzheimer's disease and Parkinson's disease.

The invention belongs to the field of biology, and particularly relates to a human colon cancer drug-resistant cell strain and application thereof. The human colon cancer cell drug-resistant cell strain is constructed for the first time, and can be used for researching a molecular mechanism of a tumor on drug resistance of a topoisomerase I inhibitor and a method for reversing tumor drug resistance, screening other anti-tumor drugs, discovering tumor drug-resistant markers, screening and evaluating novel anti-tumor drugs and the like. The method has high scientific research and production application values.

The invention relates to a method for producing an anthraquinone compound by using actinomycetes Nocardiopsis aegyptia HDN19-252, and a preparation method of the anthraquinone compound. The invention also relates to an application of the compound in tumor resistance. The structural formula is shown in the specification. A fermentation product containing the compound can be obtained through fermentation culture of actinomycetes Nocardiopsis aegyptia HDN19-252, and then the compound is obtained through separation and purification by adopting normal-phase silica gel column chromatography, reversed-phase C-18 column chromatography, semi-preparative HPLC (High Performance Liquid Chromatography) and other methods. The invention aims to provide a novel compound which is novel in structure and has human metastatic pancreatic adenocarcinoma cell (AsPC-1) inhibitory activity from secondary metabolites derived from actinomycetes, and the compound can be used as a novel pancreatic cancer cell inhibitor for treating pancreatic cancer.

The invention discloses a nano acanthopanax preparation medicine and a preparation method thereof, and relates to the technical field of acanthopanax preparation, and the acanthopanax preparation medicine comprises water, a plant raw material composition, a nano carrier material, an antioxidant, a surface modifier, a preservative, a coloring agent and a vitamin composition. Meanwhile, the antioxidant added in the prescription and the pH environment optimized in the process protect active ingredients of the acanthopanax from oxidative degradation, and provide potential passive or active targeting ability for anti-tumor, anti-inflammatory and other applications of the acanthopanax; the natural conformation and activity of heat-sensitive active ingredients are reserved to the maximum extent through the mild preparation process, management, visualization and storage are carried out on preparation data of the acanthopanax senticosus preparation medicine and corresponding analysis results, management of the acanthopanax senticosus preparation medicine through internet cloud management and control is facilitated, and the intelligent level of management of the acanthopanax senticosus preparation medicine is improved.

The invention relates to a preparation method and application of injectable nano-motor hydrogel. The preparation method comprises a preparation method of nano-motors (NMs) and a preparation method of injectable hydrogel. The NMs move autonomously by taking oxygen as a power source, and the nano particles are formed by self-assembly of bowl-shaped polydopamine nano particles (PDA NBs), nano platinum (Pt NPs) and hexadecacarboxyl zinc phthalocyanine (ZnPc) through intermolecular interaction. Hydrogen peroxide (H2O2) is used as fuel, and Pt NPs catalyzes H2O2 to generate O2, so that the nano bowl is pushed to move. The gel material of the injectable hydrogel is chitosan, and the injectable hydrogel with good stability can be prepared by adjusting the proportion of different components. The injectable nano-motor hydrogel prepared by the invention has a wide application prospect in the fields of drug sustained release, tumor resistance and the like.

The invention discloses a linear long-chain compound containing valine thiazole as well as a preparation method and application of the linear long-chain compound, and belongs to the technical field of medicinal chemistry. The structure of the linear long-chain compound containing valine thiazole is shown in the specification. The valinethiazole-containing linear long-chain compound has the beneficial effects that the valinethiazole-containing linear long-chain compound provided by the invention is novel in structure, the compound 6, the compound 9, the compound 11 and the compound 13 are good in safety, particularly, the MDR reverse activity of the compound 9 on a human oral epidermoid cancer cell line KBV is higher than that of a positive control drug verapamil, the effect is improved by 8 times compared with that of verapamil, and the compound 6, the compound 9, the compound 11 and the compound 13 can be used for preparing the valinethiazole-containing linear long-chain compound. Compared with Dysoxylactam A, the reverse multiple of the Dysoxylactam A is obviously improved from 174.3 times to 288.5 times, and the Dysoxylactam A has the application prospect of becoming a novel tumor drug resistance reversal agent.

The invention relates to a novel organic arsine compound Z2-A-Z2 and an application of the novel organic arsine compound Z2-A-Z2 in tumor resistance. The organic arsine compound Z2-A-Z2 disclosed by the invention not only shows remarkable anti-DLBCL activity in an in-vitro experiment, but also can effectively induce tumor cell apoptosis; in an animal model, the compound also shows a good anti-tumor effect, has no obvious toxic or side effect and has an important clinical application value. As an epigenetic regulating agent, Z2-A-Z2 not only shows good anti-tumor activity to DLBCL, but also has the characteristics of low toxicity and high selectivity, and has clinical transformation potential. Besides, Z2-A-Z2 can also be applied to other malignant tumors (such as multiple myeloma and T cell lymphoma) depending on an epigenetic mechanism, or can be combined with existing targeted drugs and immunotherapy, so that the comprehensive curative effect of tumor treatment is improved.

The invention discloses an application of an ethyl piperazine chromene compound in tumor resistance, and belongs to the technical field of medical chemistry. The ethyl piperazine chromene compound is 3-(4-chlorphenyl)-8-[(4-ethyl piperazine-1-yl) methyl]-7-hydroxy-2H-chromene-2-ketone, and the structural formula of the ethyl piperazine chromene compound is shown in the description. Experiments prove that the compound has a relatively strong inhibition effect on various human tumor cells such as breast cancer HCC1806, osteosarcoma MG63, liver cancer LM3, colorectal cancer HCT-8 and the like. Wherein under the concentration of 5 [mu] M, the survival rate of the compound to HCC1806 cells is inhibited to 9.4%, a strong inhibition effect on the intractable breast cancer subtype is shown, and a comprehensive result shows that the ethyl piperazine chromene compound can provide a new candidate molecule for broad-spectrum antitumor drugs.

The invention discloses a novel TCR-CAR plasmid for expressing flagellin, a CAR-T cell, a preparation method of the novel TCR-CAR plasmid and the CAR-T cell, and application of the novel TCR-CAR plasmid and the CAR-T cell in tumor resistance, and belongs to the technical field of CAR-T cells. By means of the innovative structural design, after CAR recognizes a target antigen, expression and secretion of flagellin can be started along with activation of T cells, the flagellin is released to a tumor site, after an activation signal disappears, release of the flagellin gradually fades away, and after the target antigen is recognized again, a new round of secretion and release is started. The technical problems that in the prior art, release of flagellin polypeptide cannot be accurately controlled, engineering immune cells release randomly, and then the anti-tumor effect cannot be achieved due to the fact that the engineering immune cells cannot effectively enter the tumor in the application of treating solid tumors can be effectively solved.

The invention belongs to the technical field of microorganisms, and discloses clostridium RJ-1 for producing collagenase, a product containing the clostridium and application of the clostridium RJ-1 in tumors. The strain is preserved in Guangdong Microbial Culture Collection Center (GDMCC) on June 27, 2024, and the preservation number is GDMCC 64809. The bacterial strain simultaneously expresses collagenase and generates iron-containing particles through mineralization in bacteria, the secreted collagenase degrades existing collagen grids and shows degradation characteristics related to collagen concentration, the released iron-containing particles generate ferrous ions in a lysosome acid environment after self-dissolution, and the iron-containing particles generate iron ions in the lysosome acid environment. Ferroptosis is subsequently induced by a Fenton reaction with cellular uptake. In a tumor mouse model with dense collagen, good tolerance can be achieved through single intravenous injection, huge tumors with the size of about 1000 mm < 3 > can be rapidly dissolved, and potential clinical application value is shown.

The invention discloses a traditional Chinese medicine nano-tablet for targeting pleural tumor and a preparation process thereof. The traditional Chinese medicine nano-tablet comprises the following components: hairyvein agrimony, asparagus cochinchinensis, oldenlandia diffusa, sculellaria barbata, astragalus membranaceus, pangolin scales, lumbricus, selfheal, radix scrophulariae, lithospermum, radices trichosanthis, aspongopus, liquorice, Mitsubishi, curcuma zedoary, ground beetle, centipede and bungarus parvus. The invention has the advantages of strong targeting property, high bioavailability, immunomodulatory effect and multi-way tumor resistance.

Relates to a polyethylene glycol micromolecule medicine and a preparation method and application thereof. Specifically, the invention relates to a compound as shown in a formula I or pharmaceutically acceptable salts thereof, intermediate compounds as shown in a formula II and a formula V thereof, a method for preparing the compound, and an application of the compound in tumor resistance. Biological tests show that the compound has a remarkable inhibiting effect on tumors such as breast cancer, intestinal cancer, non-small cell lung cancer, melanoma, oral squamous cell carcinoma and osteosarcoma.